S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma

Exclusion Criteria

• •* Diffuse large (formerly Working Formulation Groups F, G, H)
• •* High-grade, Burkitt's or Burkitt-like
• •* Primary mediastinal
• •* Anaplastic large cell
• •* Mantle cell
• •* Note: patients being registered to this study at first relapse must not be suitable for transplant or aggressive treatment at first relapse
• •Patients must have measurable disease; all techniques used to measure disease must be completed within 28 days prior to registration and must have been done after completion of prior therapy
• •Patients must have had a chest x-ray or CT scan of the chest and a CT scan of the abdomen and pelvis within 28 days prior to registration and they must have been done after completion of prior chemotherapy
• •Patients must have either a unilateral or bilateral bone marrow aspirate and biopsy within 42 days prior to registration
• •Patients must have had 1 or 2 prior chemotherapy regimens (pre-induction and autologous bone marrow transplantation will be considered as one prior therapy) for lymphoma; this includes investigational agents and/or other antibody therapies; all prior therapy must have been completed at least 2 weeks prior to registration; due to possible interactions with the rituximab antibody; patients previously receiving rituximab must have completed rituximab therapy at least 12 weeks prior to registration; if rituximab is given as a single agent after a relapse, it is considered a separate regimen and will be counted as such; if the rituximab is given in combination for either the first or second relapse or as consolidation after chemotherapy regimen without an intervening relapse, it will be considered part of the combination regimen and counted as one prior therapy; patients must have recovered from any chemotherapy-related toxicities prior to registration
• +24 more criteria